HCM
BNTC icon

Highbridge Capital Management’s Benitec Biopharma BNTC Stock Holding History

Highbridge Capital Management’s Portfolio BNTC Stock Details BNTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-1,055
Closed -$527K – 190
2019
Q1 		$527K Sell
1,055
-16
-1% -$6.9K 0.02% 313
2018
Q4 		$410K Hold
1,071
– – 0.01% 325
2018
Q3 		$647K Sell
1,071
-1,952
-65% -$1.33M 0.02% 415
2018
Q2 		$1.53M Buy
+3,023
New +$2.04M 0.03% 414

Other funds holding BNTC

Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
OMC
Old Mission Capital Chicago, Illinois $6.3B AUM 14.68% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Highbridge Capital Management's BNTC Position: Q2 2019 in Review

Highbridge Capital Management sold out of Benitec Biopharma (BNTC) in Q2 2019, closing a stake of 1,055 shares — an estimated $527K sold.

Highbridge Capital Management first reported a position in BNTC in Q2 2018 and held it in 4 quarters. The position peaked at $1.53M in Q2 2018. 7 funds tracked by Wall St. Rank hold BNTC as of Q2 2019.

  • Highbridge Capital Management reported no remaining Benitec Biopharma position as of Q2 2019 after selling out during the quarter.
  • Highbridge Capital Management sold 1,055 Benitec Biopharma shares in Q2 2019, an estimated $527K.
  • Highbridge Capital Management first reported a position in Benitec Biopharma in Q2 2018 and held it in 4 quarters.
  • Highbridge Capital Management's Benitec Biopharma position peaked at $1.53M in Q2 2018.
  • 7 funds tracked by Wall St. Rank held Benitec Biopharma as of Q2 2019.

Based on Highbridge Capital Management's 13F filing for Q2 2019, filed 14 Aug 2019.